about
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitorsInteraction of antiepileptic drugs with human P-glycoprotein in vitro.Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells.Interaction of progestins with the human multidrug resistance-associated protein 2 (MRP2).Drug utilization patterns and reported health status in ethnic German migrants (Aussiedler) in Germany: a cross-sectional study.No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.Inhibition of P-glycoprotein by newer antidepressants.Rifampicin alters the expression of reference genes used to normalize real-time quantitative RT-PCR data.Health care costs in the elderly in Germany: an analysis applying Andersen's behavioral model of health care utilizationDo we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics.Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.Impact of ATP-binding cassette transporters on human immunodeficiency virus therapy.Drug interactions with phytotherapeutics in oncology.Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver.Patients' beliefs about medicines in a primary care setting in Germany.Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the Medication Adherence Report Scale (MARS) in Germany.Risk factors of adverse health outcomes after hospital discharge modifiable by clinical pharmacist interventions: a review with a systematic approach.Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.Comparison of Nine Instruments to Calculate Anticholinergic Load in a Large Cohort of Older Outpatients: Association with Cognitive and Functional Decline, Falls, and Use of Laxatives.
P50
Q28279227-9FB05EFE-B44A-4727-A389-2BA37E186579Q31155945-23C38D69-7CF2-4690-9388-70EB2938E8A2Q33205916-B248FF06-CB80-4405-A2B7-B06B95F6DB06Q33220471-15F71CF8-366F-466A-A595-12C062DBD4CFQ33944845-23FDF3C9-038B-482B-9762-CD6D0872DBF1Q34151189-4CE9B5D8-7721-4996-A8B2-068517661AD3Q34185171-757114BD-6040-4C20-89BB-D51773AF8348Q34349015-2DB676D9-F9A5-43A4-935E-F9A6BB174733Q35093957-9B9AABCD-0822-4953-B97D-B465F762202AQ36289290-7FEDEE3B-452D-4EC4-8130-217D0966D72FQ36735325-88D9CBEE-31FE-42FF-8D08-071560D27D1AQ37783447-267A3688-467C-465F-890F-0734BAC4A21EQ38175476-9322C947-1248-4D91-B7FA-7123C3A3AF2FQ38322847-06ED9546-4F13-493E-B7AF-DC42AFFEE707Q38465825-4295CC17-60E8-4D0C-822B-4E908ED50ADAQ38469045-36809E99-C760-4D40-9EE1-3CF6B914B2C5Q38689913-58916DAA-DBB5-4318-9BE4-DBDE57C75BD1Q38731518-68073D34-07AC-4D0A-AA12-A10F6C78D8E6Q40320665-995F7C0D-5161-4835-AC3C-C09A1572DE40
P50
description
onderzoeker
@nl
name
Walter Emil Haefeli
@ast
Walter Emil Haefeli
@en
Walter Emil Haefeli
@es
Walter Emil Haefeli
@sl
type
label
Walter Emil Haefeli
@ast
Walter Emil Haefeli
@en
Walter Emil Haefeli
@es
Walter Emil Haefeli
@sl
prefLabel
Walter Emil Haefeli
@ast
Walter Emil Haefeli
@en
Walter Emil Haefeli
@es
Walter Emil Haefeli
@sl